Trial Outcomes & Findings for Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery (NCT NCT00909324)

NCT ID: NCT00909324

Last Updated: 2020-08-17

Results Overview

Patients rated their ocular comfort on a scale of 0 to 10 on the following parameters: Burning sensation, foreign body sensation, itching, watering of eyes, dryness of eyes, and photophobia. A higher score indicated greater discomfort. A negative change score indicated improvement.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

170 participants

Primary outcome timeframe

Baseline (Pre-LASIK surgery), Day 1, Day 7 and Day 30 post-LASIK surgery

Results posted on

2020-08-17

Participant Flow

Participant milestones

Participant milestones
Measure
Pre-LASIK 0.3% Hypromellose
Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
Post-LASIK 0.3% Hypromellose
Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
Overall Study
STARTED
72
90
Overall Study
COMPLETED
72
90
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Pre-LASIK 0.3% Hypromellose
n=72 Participants
Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
Post-LASIK 0.3% Hypromellose
n=90 Participants
Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
Total
n=162 Participants
Total of all reporting groups
Age, Continuous
26.24 Years
STANDARD_DEVIATION 4.81 • n=99 Participants
25.99 Years
STANDARD_DEVIATION 5.06 • n=107 Participants
26.10 Years
STANDARD_DEVIATION 4.93 • n=206 Participants
Sex: Female, Male
Female
50 Participants
n=99 Participants
66 Participants
n=107 Participants
116 Participants
n=206 Participants
Sex: Female, Male
Male
22 Participants
n=99 Participants
24 Participants
n=107 Participants
46 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Baseline (Pre-LASIK surgery), Day 1, Day 7 and Day 30 post-LASIK surgery

Population: Intent-to-Treat population: All patients in the study who received study treatment.

Patients rated their ocular comfort on a scale of 0 to 10 on the following parameters: Burning sensation, foreign body sensation, itching, watering of eyes, dryness of eyes, and photophobia. A higher score indicated greater discomfort. A negative change score indicated improvement.

Outcome measures

Outcome measures
Measure
Pre-LASIK 0.3% Hypromellose
n=72 Participants
Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
Post-LASIK 0.3% Hypromellose
n=90 Participants
Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
Ocular Comfort Level From Baseline to End of Study
Foreign body sensation: Day 30
0.05 Units on a scale
Standard Deviation 0.29
0.09 Units on a scale
Standard Deviation 0.33
Ocular Comfort Level From Baseline to End of Study
Watering of eyes: Day 7
0.22 Units on a scale
Standard Deviation 0.49
0.25 Units on a scale
Standard Deviation 0.49
Ocular Comfort Level From Baseline to End of Study
Burning in eyes: Post-LASIK Day 1
0.68 Units on a scale
Standard Deviation 1.18
0.84 Units on a scale
Standard Deviation 1.16
Ocular Comfort Level From Baseline to End of Study
Burning in eyes: Day 7
0.24 Units on a scale
Standard Deviation 0.52
0.31 Units on a scale
Standard Deviation 0.54
Ocular Comfort Level From Baseline to End of Study
Burning in eyes: Day 30
0.08 Units on a scale
Standard Deviation 0.33
0.07 Units on a scale
Standard Deviation 0.26
Ocular Comfort Level From Baseline to End of Study
Foreign body sensation: Post-LASIK Day 1
0.94 Units on a scale
Standard Deviation 1.47
1.09 Units on a scale
Standard Deviation 1.41
Ocular Comfort Level From Baseline to End of Study
Foreign body sensation: Day 7
0.26 Units on a scale
Standard Deviation 0.56
0.27 Units on a scale
Standard Deviation 0.55
Ocular Comfort Level From Baseline to End of Study
Itching: Post-LASIK Day 1
0.35 Units on a scale
Standard Deviation 0.77
0.71 Units on a scale
Standard Deviation 1.21
Ocular Comfort Level From Baseline to End of Study
Itching: Day 7
0.16 Units on a scale
Standard Deviation 0.48
0.32 Units on a scale
Standard Deviation 0.68
Ocular Comfort Level From Baseline to End of Study
Itching: Day 30
0.05 Units on a scale
Standard Deviation 0.22
0.13 Units on a scale
Standard Deviation 0.42
Ocular Comfort Level From Baseline to End of Study
Watering of eyes: Post-LASIK Day 1
0.71 Units on a scale
Standard Deviation 0.94
0.71 Units on a scale
Standard Deviation 0.96
Ocular Comfort Level From Baseline to End of Study
Watering of eyes: Day 30
0.10 Units on a scale
Standard Deviation 0.30
0.09 Units on a scale
Standard Deviation 0.29
Ocular Comfort Level From Baseline to End of Study
Dryness of eyes: Post-LASIK Day 1
0.82 Units on a scale
Standard Deviation 1.18
1.28 Units on a scale
Standard Deviation 1.71
Ocular Comfort Level From Baseline to End of Study
Dryness of eyes: Day 7
0.41 Units on a scale
Standard Deviation 0.72
0.72 Units on a scale
Standard Deviation 0.98
Ocular Comfort Level From Baseline to End of Study
Dryness of eyes: Day 30
0.25 Units on a scale
Standard Deviation 0.60
0.49 Units on a scale
Standard Deviation 0.84
Ocular Comfort Level From Baseline to End of Study
Photophobia: Post-LASIK Day 1
0.22 Units on a scale
Standard Deviation 0.54
0.41 Units on a scale
Standard Deviation 0.90
Ocular Comfort Level From Baseline to End of Study
Photophobia: Day 7
0.09 Units on a scale
Standard Deviation 0.33
0.09 Units on a scale
Standard Deviation 0.37
Ocular Comfort Level From Baseline to End of Study
Photophobia: Day 30
0.08 Units on a scale
Standard Deviation 0.33
0.07 Units on a scale
Standard Deviation 0.26

SECONDARY outcome

Timeframe: Baseline (Pre-LASIK surgery), Day 1, Day 7 and Day 30 post-LASIK surgery

Population: Intent-to-Treat population: All patients in the study who received study treatment.

The time required for dry spots to appear on the corneal surface after blinking. Sodium fluorescein dye is added to the eye and the tear film is observed under a slit lamp while the patient avoids blinking until tiny dry spots develop. The longer it takes, the more stable the tear film. A short tear breakup time is a sign of a poor tear film. Generally, \>10 seconds is thought to be normal, 5 to 10 seconds marginal, and \<5 seconds low (with high likelihood of dry eye symptoms), ie, a shorter time indicates greater eye dryness. A positive change score indicates improvement.

Outcome measures

Outcome measures
Measure
Pre-LASIK 0.3% Hypromellose
n=72 Participants
Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
Post-LASIK 0.3% Hypromellose
n=90 Participants
Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
Tear Breakup Time From Baseline to End of Study
Post-LASIK Day 1
14.60 Seconds
Standard Deviation 6.06
12.47 Seconds
Standard Deviation 6.20
Tear Breakup Time From Baseline to End of Study
Day 7
13.47 Seconds
Standard Deviation 6.22
10.84 Seconds
Standard Deviation 3.58
Tear Breakup Time From Baseline to End of Study
Day 30
13.63 Seconds
Standard Deviation 5.36
12.70 Seconds
Standard Deviation 5.38

SECONDARY outcome

Timeframe: Baseline (Pre-LASIK surgery), Day 1, Day 7 and Day 30 post-LASIK surgery

Population: Intent-to-Treat population: All patients in the study who received study treatment.

Schirmer's test determines tear production, and whether the eye produces enough tears to keep it moist. A small strip of filter paper is inserted inside the lower eyelid of each eye and the eyes are closed for 5 minutes. The paper is then removed and the length of paper that is moist is measured. A young person normally moistens 15 mm of the paper. The shorter the length of moist paper, the dryer the eyes. A positive change score indicates improvement.

Outcome measures

Outcome measures
Measure
Pre-LASIK 0.3% Hypromellose
n=72 Participants
Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
Post-LASIK 0.3% Hypromellose
n=90 Participants
Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
Results of Schirmer's Test From Baseline to End of Study
Left eye: Post-LASIK Day 1
19.64 mm
Standard Deviation 8.50
17.21 mm
Standard Deviation 7.10
Results of Schirmer's Test From Baseline to End of Study
Left eye: Day 7
17.68 mm
Standard Deviation 9.93
17.93 mm
Standard Deviation 5.43
Results of Schirmer's Test From Baseline to End of Study
Left eye: Day 30
21.70 mm
Standard Deviation 13.01
18.77 mm
Standard Deviation 7.11
Results of Schirmer's Test From Baseline to End of Study
Right eye: Post-LASIK Day 1
22.65 mm
Standard Deviation 7.10
13.70 mm
Standard Deviation 2.91
Results of Schirmer's Test From Baseline to End of Study
Right eye: Day 7
22.78 mm
Standard Deviation 0.49
15.25 mm
Standard Deviation 0.49
Results of Schirmer's Test From Baseline to End of Study
Right eye: Day 30
22.89 mm
Standard Deviation 2.47
18.35 mm
Standard Deviation 3.83

Adverse Events

Pre-LASIK 0.3% Hypromellose

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Post-LASIK 0.3% Hypromellose

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Study Director

Novartis Pharmaceuticals

Phone: + 1 862 778 8300

Results disclosure agreements

  • Principal investigator is a sponsor employee The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.
  • Publication restrictions are in place

Restriction type: OTHER